Partnering to Explore New Possibilities in Diabetes Research
INVC NEWS New Delhi, The Minister of State for Science & Technology and Earth Sciences, Shri Y.S. Chowdary, presided over the Memorandum of Agreement (MoA) signing ceremony between the Drug Discovery Research Centre (DDRC) and Revelations Biotech Pvt. Ltd. (RBPL), a Hyderabad based Research and Development Company. DDRC is a niche Centre of the Translational Health Science and Technology Institute (THSTI) Faridabad, of the Department of Biotechnology, Government of India. The research collaboration will focus on developing new approaches for diagnosis and treatment of Diabetes. The Minister said that sadly India stands out as the diabetic capital of the world and the continuing increase in incidence of this disease is a cause of serious concern. Diabetes is a gateway to a host of other diseases and hence needs to be checked on its very onset. He further said that if we spend Rs.100 for the prevention of a disease then we save around Rs.400 which would otherwise be spent on the curation process. He gave a motto ‘Illness to Wellness’ for this drive to find a preventive measure to pre-empt and prevent Diabetes at very early stages. Shri Chowdary also laid stress on the importance of Translational Research which leads to translation of cutting edge research works by scientists in their labs to manufacturing low cost drugs for the masses, with the contribution from the private sector. The annual expenditure for Diabetes treatment in India is to the tune of Rs. 1.5 lakh crores. Diabetes is a chronic progressive metabolic disorder that is characterized by chronic hyperglycemia with disturbances of carbohydrate, fat, and protein metabolism.Although previously thought to represent a problem of ‘middle-age’ but recently there has been a rapid rise in incidence of Diabetes in the youth as well. This is largely due to lifestyle changes where a high calorie diet is coupled with sedentary habits. Hence there is an urgent need for more sensitive methods for detection and for more effective regimens for treatment. Prof. K. VijayRaghavan, Secretary, Department of Bio-technology, speaking at the occasion said that the DDRC-RBPL collaboration will focus on addressing these needs through two separate programs. Firstly, to develop a data based software package that will not only identify individuals who are becoming susceptible to diabetes but also predict the future course of disease in those who are already diabetic. It is hoped that the advance warning provided by such a system will allow the target individuals to pre-emptively make appropriate lifestyle alterations so as to mitigate the disease onset and prevent its progression. The second program is to develop a new drug that will prevent re-absorption of glucose in the kidneys. This re-absorption process contributes to maintain high glycemic levels in diabetics. Inhibition of this process by an effective drug therefore will lead to a significant lowering of blood glucose levels.